Financial Review: Utah Medical Products (UTMD) and Antares Pharma (ATRS)

Utah Medical Products (NASDAQ: UTMD) and Antares Pharma (NASDAQ:ATRS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings.

Profitability

This table compares Utah Medical Products and Antares Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Utah Medical Products	32.98%	17.91%	15.95%
Antares Pharma	-34.27%	-41.37%	-25.74%

Risk & Volatility

Utah Medical Products has a beta of 0.74, meaning that its share price is 26% less volatile than the S&P 500. Comparatively, Antares Pharma has a beta of 0.4, meaning that its share price is 60% less volatile than the S&P 500.

Dividends

Utah Medical Products pays an annual dividend of $1.06 per share and has a dividend yield of 1.5%. Antares Pharma does not pay a dividend. Utah Medical Products pays out 30.4% of its earnings in the form of a dividend.

Institutional & Insider Ownership

65.2% of Utah Medical Products shares are owned by institutional investors. Comparatively, 32.9% of Antares Pharma shares are owned by institutional investors. 9.1% of Utah Medical Products shares are owned by insiders. Comparatively, 11.6% of Antares Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Utah Medical Products and Antares Pharma’s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	EBITDA	Earnings Per Share	Price/Earnings Ratio
Utah Medical Products	$39.60 million	6.81	$20.09 million	$3.49	20.77
Antares Pharma	$53.10 million	9.01	-$15.90 million	($0.12)	-25.50

Utah Medical Products has higher revenue, but lower earnings than Antares Pharma. Antares Pharma is trading at a lower price-to-earnings ratio than Utah Medical Products, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and target prices for Utah Medical Products and Antares Pharma, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Utah Medical Products	0	0	0	0	N/A
Antares Pharma	0	0	3	1	3.25

Antares Pharma has a consensus target price of $4.58, indicating a potential upside of 49.51%. Given Antares Pharma’s higher possible upside, analysts clearly believe Antares Pharma is more favorable than Utah Medical Products.

Summary

Utah Medical Products beats Antares Pharma on 8 of the 15 factors compared between the two stocks.

Utah Medical Products Company Profile

Utah Medical Products, Inc. (UTMD) is engaged in the business of producing medical devices that are disposable and for hospital use. The Company’s product categories include labor and delivery/obstetrics, including fetal monitoring accessories, Vacuum-Assisted Delivery Systems (VAD), and other labor and delivery tools; neonatal intensive care, including DISPOSA-HOOD, DELTRAN PLUS and GESCO; gynecology/urology/electrosurgery, including LETZ System, FINESSE+ Generator, EPITOME, PATHFINDER PLUS, HOLMIUM LASER FIBRES, LIBERTY System, ENDOCURETTE, TVUS/HSG-Cath and LUMIN, and blood pressure monitoring, including DELTRAN Disposable Pressure Transducer (DPT), and pressure monitoring accessories, components and other molded parts. UTMD markets a range of medical devices used in critical care areas, especially the neonatal intensive care unit, the labor and delivery department and the women’s health center in hospitals, as well as products sold to outpatient clinics and physician’s offices.

Antares Pharma Company Profile

Antares Pharma, Inc. (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops, manufactures and commercializes therapeutic products using its drug delivery systems. Its subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injector system suitable for branded and generic injectable drugs in unit dose containers, reusable needle-free spring-action injector devices, and disposable multi-use pen injectors for use with cartridges. The Company makes a reusable, needle-free spring action injection device, ZOMA-Jet or Twin-Jector, which is marketed through its partners for use with human growth hormone (hGH). The Company operates through drug delivery segment, which includes self-administered parenteral pharmaceutical products and technologies.